Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › avelumab

avelumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of avelumab

34 trials tracked of avelumab: 6 in phase 3 or 4 and 6 with published results. The most-cited published study has 503 citations.

34Trials tracked
6Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 3 6 Phase 2 17 Phase 1 5 Other / NA 6
  1. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 503 cited
  2. Phase 3 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) Completed · 399 cited
  3. Phase 3 Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Completed · 397 cited
  4. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 222 cited
  5. Phase 3 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Completed · 208 cited
  6. Phase 3 Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed · 21 cited
Show 28 more trials
  1. Phase 2 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Completed
  2. Phase 2 OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Completed
  3. Phase 2 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) Completed
  4. Phase 2 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Completed
  5. Phase 2 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Completed
  6. Phase 2 Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Completed
  7. Phase 2 PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer Completed
  8. Phase 2 Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme Completed
  9. Phase 2 Avelumab for People With Recurrent Respiratory Papillomatosis Completed
  10. Phase 2 Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma Completed
  11. Phase 2 Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Completed
  12. Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed
  13. Phase 2 Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC Completed
  14. Phase 2 Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Completed
  15. Phase 2 Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer Completed
  16. Phase 2 Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma Completed
  17. Phase 2 Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Completed
  18. Phase 1 Study of Avelumab-M3814 Combinations Completed
  19. Phase 1 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Completed
  20. Phase 1 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Completed
  21. Phase 1 Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer Completed
  22. Phase 1 Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy Completed
  23. N/A A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Completed
  24. N/A Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) Completed
  25. N/A A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy Completed
  26. N/A Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) Completed
  27. N/A A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread Completed
  28. N/A To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients
Gastroenterology RCT
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients
This randomized phase II trial evaluated adding avelumab to cetuximab in RAS/BRAF wild-type metastatic colorectal cancer patients.
A new trial shows adding avelumab to cetuximab improves survival only for patients without certain genetic changes, not for everyone.
May 1, 2026
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
Oncology Meta-analysis
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Frontiers Apr 27, 2026
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026